We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Genzyme and Brookwood Announce Collaboration

Genzyme and Brookwood Announce Collaboration

Genzyme and Brookwood Announce Collaboration

Genzyme and Brookwood Announce Collaboration

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genzyme and Brookwood Announce Collaboration "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, and Brookwood Pharmaceuticals, Inc., have announced a broad collaboration to develop drug delivery solutions, with an initial focus on peptide delivery.

The partnership offers customized solutions for parenteral formulations by combining expertise in design for peptide delivery, peptide synthesis, and drug delivery technologies.

The 'Design for Peptide Delivery' approach optimizes peptide physical and chemical properties early on in drug development, so as to match a peptide with the properties of microparticles, implants and other drug delivery formulations required for optimal drug delivery.

Combining the capabilities and knowledge of Genzyme and Brookwood in parallel design of peptide and delivery systems will result in clients developing sophisticated pharmaceutical products that will benefit the patient.

"Brookwood Pharmaceuticals' scientific team has industry-leading experience in a wide range of drug delivery systems, with particular depth in long-acting parenterals such as microparticles and solid implants," said Dan Hayden, Senior Vice President and General Manager of Genzyme Pharmaceuticals.

"Combining Brookwood's strengths with Genzyme's expertise in custom GMP peptide development and manufacturing provides a powerful service to peptide drug delivery customers."

In the longer term many drug delivery technologies can be developed from the portfolio of materials and technologies owned by Genzyme and Brookwood.

"By working with an industry leader like Genzyme, we envision this collaboration to generate plenty of energy, creativity, and new drug delivery solutions and products, from which our clients will greatly benefit," said Arthur Tipton, Ph.D., president and CEO of Brookwood Pharmaceuticals.

"From our experience in peptide delivery, we have learned that focus on peptide modification and peptide properties can greatly aid in the stability and performance of a peptide drug delivery product."

Rather than promoting a specific technology, the Genzyme-Brookwood collaboration will offer customers a solution-oriented approach through synergistic capabilities and technologies, depending on the peptide and the customer's target drug profile.

Customers will also benefit from enhanced capabilities and services such as research-scale peptide synthesis for backbone and side chain modifications, evaluation of available drug delivery technologies, large-scale peptide drug substance production, formulation feasibility studies and development of micro-encapsulation processes, drug excipients manufacturing (phospholipids and polymers), drug product formulation, and manufacturing of clinical supplies and final drug delivery product.